MTOR and neoplasm: Although the mTOR inhibitor rapamycin is primarily used as an immunosuppressant in transplant patients because it reduces B and T cell numbers, as well as for arresting tumor cell growth and progression, it is now evident that mTOR inhibition may actually favor increased numbers of certain subsets of immune cells that favor low mTOR activity and reduced mitochondrial energy expenditure.